Department of Immunology and Allergy, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mult Scler Relat Disord. 2019 Apr;29:68-82. doi: 10.1016/j.msard.2019.01.025. Epub 2019 Jan 24.
The majority of patients with multiple sclerosis (MS) suffer from central neuropathic pain (CNP). Using experimental autoimmune encephalomyelitis (EAE) model, only a few experiments were performed to assess pain behaviors in MS. To address this issue, complete Freund's adjuvant (CFA) was replaced with an acylated triterpene glycoside saponin adjuvant named quillaja saponin-21 (QS-21) to develop CNP in the EAE mouse model. The deacylated form of QS-21, named QT-0101, has been suggested to have an immunomodulatory effect. Thus, QT-0101 was used as a vaccine adjuvant to modulate the immune system against myelin oligodendrocyte glycoprotein (MOG35-55) antigen.
In this study, C57BL/6 mice, except for mice in the negative control (PBS) and MOG groups, were divided into three groups and immunized by MOG35-55 emulsified with CFA, QS-21, or QT-0101 adjuvants, respectively. Thermal hyperalgesia, as a CNP clinical manifestation, through the Hot Plate test and the clinical signs, was assessed for 60 days after immunization. On days 21 and 60, mice were sacrificed and the frequency of TCD4, TCD8, IL-17, IL-4, and CD25/FoxP3 cells population in the total splenocytes population was assessed by flow cytometry. Infiltration of Leukocytes into the brain and demyelination of white matter were also evaluated by histopathologic studies.
Our results revealed that unlike the MOG+QT-0101 group, the MOG+QS-21 and MOG+CFA groups represented clinical symptoms that mimic the mild relapsing-remitting and monophasic models, respectively. Thermal hyperalgesia, as a CNP clinical manifestation, developed in the bilateral hind paws in the MOG+CFA and MOG+QS-21 mice groups during the onset of neurologic deficits, but it is maintained until completion of the study only in MOG+QS-21 mice group. The frequency of TCD4, TCD8 and IL-17 cells population in the MOG+QS-21 and MOG+CFA mice groups, as well as IL-4 and CD25/Foxp3 cells population in the MOG+QT-0101 mice group, significantly increased in comparison with the PBS mice group. Infiltration of inflammatory cells increased significantly in the MOG+QS-21 and MOG+CFA mice groups compared with the PBS mice group. Demyelination of white matter was identified significantly only in the MOG+CFA mice group compared with the PBS mice group.
These results showed that QS-21 is a suitable adjuvant for the establishment of a mild relapsing-remitting EAE model for CNP development and open a new avenue to future pre-clinical and clinical research studies related to CNP treatment. Nevertheless, QT-0101 seems to have the potential to act as a vaccine adjuvant with immunomodulatory property against auto-antigens.
大多数多发性硬化症(MS)患者患有中枢神经性疼痛(CNP)。使用实验性自身免疫性脑脊髓炎(EAE)模型,仅进行了少数实验来评估 MS 中的疼痛行为。为了解决这个问题,用酰化三萜糖苷皂苷佐剂 Quillaja saponin-21(QS-21)代替完全弗氏佐剂(CFA)来开发 EAE 小鼠模型中的 CNP。QS-21 的去酰化形式,称为 QT-0101,被认为具有免疫调节作用。因此,QT-0101 被用作疫苗佐剂来调节针对髓鞘少突胶质细胞糖蛋白(MOG35-55)抗原的免疫系统。
在这项研究中,除了阴性对照(PBS)和 MOG 组的小鼠外,C57BL/6 小鼠被分为三组,分别用 MOG35-55 乳化的 CFA、QS-21 或 QT-0101 佐剂免疫。通过热板试验和临床症状评估免疫后 60 天的热痛觉过敏,作为 CNP 的临床表现。在第 21 天和第 60 天,处死小鼠,通过流式细胞术评估总脾细胞群体中 TCD4、TCD8、IL-17、IL-4 和 CD25/FoxP3 细胞群体的频率。通过组织病理学研究还评估了白细胞浸润和白质脱髓鞘。
我们的结果表明,与 MOG+QT-0101 组不同,MOG+QS-21 和 MOG+CFA 组分别代表类似于轻度复发缓解和单相模型的临床症状。热痛觉过敏,作为 CNP 的临床表现,在 MOG+CFA 和 MOG+QS-21 小鼠组的神经功能缺损发作时出现在双侧后爪,但仅在 MOG+QS-21 小鼠组持续到研究结束。MOG+QS-21 和 MOG+CFA 小鼠组的 TCD4、TCD8 和 IL-17 细胞群体以及 MOG+QT-0101 小鼠组的 IL-4 和 CD25/Foxp3 细胞群体的频率与 PBS 小鼠组相比显著增加。与 PBS 小鼠组相比,MOG+QS-21 和 MOG+CFA 小鼠组的炎症细胞浸润显著增加。与 PBS 小鼠组相比,仅在 MOG+CFA 小鼠组中发现白质脱髓鞘显著。
这些结果表明 QS-21 是一种适合建立用于 CNP 发展的轻度复发缓解性 EAE 模型的佐剂,并为未来与 CNP 治疗相关的临床前和临床研究开辟了新途径。然而,QT-0101 似乎具有作为针对自身抗原的具有免疫调节特性的疫苗佐剂的潜力。